Rare Disease Trial, Recruiting NCT04923178 Sponsor: National Cancer Institute (NCI) Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT04923178
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a urothelial or rare genitourinary (urinary/reproductive system) cancer that has been confirmed through a tissue or cell sample test. This includes a wide range of cancer types, such as:
    • Small cell carcinoma of the bladder
    • Adenocarcinoma of the bladder
    • Squamous cell carcinoma of the bladder
    • Plasmacytoid urothelial carcinoma
    • Any type of penile cancer
    • Any type of testicular cancer
    • Sarcomatoid renal cell carcinoma (a type of kidney cancer)
    • Sarcomatoid urothelial carcinoma
    • Renal medullary carcinoma
    • Rare subtypes of urothelial carcinoma, including micropapillary, giant cell, lipid-rich, clear cell, and nested variants
    • Large cell neuroendocrine carcinoma
    • Lymphoepithelioma-like carcinoma
    • Mixed cancer patterns
    • Small cell neuroendocrine prostate cancer
    • Testicular Sertoli or Leydig cell tumours
    • Other genitourinary cancers, at the lead doctor's discretion
  • People aged 18 years or older
  • People who are able to understand the study and are willing to sign a written consent form

Who may not be able to join:

  • No exclusion criteria have been listed for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrea B Apolo, M.D., National Cancer Institute (NCI)

Phone: (240) 858-3236

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
24 October 2022
Est. completion
1 December 2041

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

natural history of urothelial and rare genitourinary cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov